PHASE I/IIA STUDY OF THE ORAL 5-AZACITIDINE IN COMBINATION WITH THE HISTONE DEACETYLASE INHIBITOR ROMIDEPSIN FOR THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY LYMPHOID MALIGNANCIES

Trial Profile

PHASE I/IIA STUDY OF THE ORAL 5-AZACITIDINE IN COMBINATION WITH THE HISTONE DEACETYLASE INHIBITOR ROMIDEPSIN FOR THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY LYMPHOID MALIGNANCIES

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs Azacitidine (Primary) ; Romidepsin (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma; T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Aug 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2019.
    • 09 Aug 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
    • 17 Aug 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Nov 2015 to 1 Feb 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top